Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology 2026 Open access

Read full text
Authors: Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima
DOI: 10.1111/bjh.70490
Cited by: 1
References: 22

Abstract

Functional high-risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12-24 months of front-line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front-line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less effective front-line therapy. In this study, we combined data from three Center for International Blood and Marrow Transplant Research studies (MM18-02, MM19-01 and MM20-03). We included patients who received front-line AHSCT between 2008 and 2018 and had progression

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Cancer Treatment and Pharmacology

Publication details

Journal / source
British Journal of Haematology
Publisher
Wiley
Volume
208
Issue
6
Pages
2134–2142
Publication date
23 April 2026
Language
EN